A TriKE recognizing CD16, CD19 and IL-15 cytokine can activate the NK cells from healthy donors and cause killing of CLL cells, showing promising efficacy in refractory CLL (137). This evidence concerns the gene FCGR3A and B-cell chronic lymphocytic leukemia.